**Appendix**

**Table 3**. Conditional/restricted (i.e. LWC/LWCMEA) drug-indication pairs included in our analysis and the links to their respective final HTA recommendation reports

|  |  |  |  |
| --- | --- | --- | --- |
| **HTA Agency** | **Molecule name** | **Type of restricted recommendation decision (LWC/LWCMEA)** | **Source** |
| NICE | Pixantrone | LWCMEA | <https://www.nice.org.uk/guidance/ta306/chapter/1-Guidance> |
| SMC | Ipilimumab-2 | LWCMEA | <https://www.scottishmedicines.org.uk/medicines-advice/ipilimumab-yervoy-fullsubmission-99714/> |
| NICE | Ipilimumab-2 | LWCMEA | <https://www.nice.org.uk/guidance/ta319/chapter/1-Guidance> |
| PBAC | Osimertinib  | LWCMEA | <https://www.pbs.gov.au/industry/listing/elements/pbac-meetings/psd/2018-11/files/osimertinib-psd-november-2018.pdf> |
| SMC | Osimertinib  | LWCMEA | <https://www.scottishmedicines.org.uk/medicines-advice/osimertinib-tagrisso-fullsubmission-121417/> |
| TLV | Osimertinib  | LWCMEA | <https://www.tlv.se/beslut/beslut-lakemedel/generell-subvention/arkiv/2017-10-03-tagrisso-ingar-i-hogkostnadsskyddet.html> |
| NICE | Osimertinib  | LWCMEA | <https://www.nice.org.uk/guidance/ta416/chapter/1-Recommendations> |
| PBAC | Afatinib-1 | LWCMEA | <http://www.pbs.gov.au/info/industry/listing/elements/pbac-meetings/psd/2013-07/afatinib-first-line> |
| SMC | Afatinib-1 | LWCMEA | <https://www.scottishmedicines.org.uk/medicines-advice/afatinib-giotrif-fullsubmission-92013/> |
| TLV | Afatinib-1 | LWCMEA | <https://www.tlv.se/beslut/beslut-lakemedel/generell-subventiorkiv/2014-04-29-giotrif-ingar-i-hogkostnadsskyddet.html> |
| NICE | Afatinib-1 | LWCMEA | <https://www.nice.org.uk/guidance/ta310/chapter/1-Guidance> |
| PBAC | Cabozantinib-2 | LWC | <http://www.pbs.gov.au/info/industry/listing/elements/pbac-meetings/psd/2017-12/cabozantinib-psd-december-2017> |
| TLV | Cabozantinib-2 | LWC | <https://www.tlv.se/beslut/beslut-lakemedel/begransad-subvention/arkiv/2015-02-06-cometriq-ingar-i-hogkostnadsskyddet-med-begransning.html> |
| NICE | Cabozantinib-2 | LWCMEA | <https://www.nice.org.uk/guidance/ta516/chapter/1-Recommendations> |
| SMC | Olaratumab | LWCMEA | <https://www.scottishmedicines.org.uk/medicines-advice/olaratumab-lartruvo-fullsubmission-127317/> |
| NICE | Olaratumab | LWCMEA | <https://www.nice.org.uk/guidance/ta465/chapter/1-Recommendations> |
| PBAC | Bevacizumab-1 | LWCMEA | <http://www.pbs.gov.au/info/industry/listing/elements/pbac-meetings/psd/2014-03/Bevacizumab> |
| SMC | Bevacizumab-1 | LWC | <https://www.scottishmedicines.org.uk/medicines-advice/bevacizumab-avastin-resubmission-80612/> |
| SMC | Pembrolizumab-2 | LWCMEA | <https://www.scottishmedicines.org.uk/medicines-advice/pembrolizumab-keytruda-fullsubmission-120417/> |
| NICE | Pembrolizumab-2 | LWCMEA | <https://www.nice.org.uk/guidance/ta428> |
| SMC | Daratumumab | LWCMEA | <https://www.scottishmedicines.org.uk/medicines-advice/daratumumab-darzalex-resubmission-120517/> |
| NICE | Daratumumab | LWCMEA | <https://www.nice.org.uk/guidance/ta510> |
| PBAC | Alectinib | LWC | <http://www.pbs.gov.au/info/industry/listing/elements/pbac-meetings/psd/2017-07/alectinib-psd-july-2017> |
| PBAC | Bortezomib-1 | LWC | <http://www.pbs.gov.au/info/industry/listing/elements/pbac-meetings/psd/2012-03/bortezomib> |
| SMC | Bortezomib-1 | LWC | <https://www.scottishmedicines.org.uk/medicines-advice/bortezomib-velcade-fullsubmission-92713/> |
| PBAC | Idelalisib-1 | LWCMEA | <https://www.pbs.gov.au/industry/listing/elements/pbac-meetings/psd/2016-07/files/idelalisib-cll-psd-july-2016.pdf> |
| SMC | Idelalisib-1 | LWCMEA | <https://www.scottishmedicines.org.uk/medicines-advice/idelalisib-zydelig-fullsubmission-102615/> |
| TLV | Idelalisib-1 | LWC | <https://www.tlv.se/beslut/beslut-lakemedel/generell-subventiorkiv/2015-03-09-zydelig-ingar-i-hogkostnadsskyddet.html> |
| NICE | Idelalisib-1 | LWCMEA | <https://www.nice.org.uk/guidance/ta359/chapter/1-Guidance> |
| PBAC | Olaparib | LWCMEA | <https://www.pbs.gov.au/industry/listing/elements/pbac-meetings/psd/2018-03/files/olaparib-psd-march-2018.pdf> |
| SMC | Olaparib | LWCMEA | <https://www.scottishmedicines.org.uk/medicines-advice/olaparib-lynparza-resubmission-104715/> |
| NICE | Olaparib | LWCMEA | <https://www.nice.org.uk/guidance/ta381/chapter/1-Recommendations> |
| PBAC | Eribulin-1 | LWCMEA | <http://www.pbs.gov.au/info/industry/listing/elements/pbac-meetings/psd/2013-11/eribulin> |
| NICE | Eribulin-1 | LWCMEA | <https://www.nice.org.uk/guidance/ta423> |
| PBAC | Palbociclib | LWCMEA | <http://www.pbs.gov.au/info/industry/listing/elements/pbac-meetings/psd/2017-11/palbociclib-psd-november-2017> |
| SMC | Palbociclib | LWCMEA | <https://www.scottishmedicines.org.uk/medicines-advice/palbociclib-ibrance-fullsubmission-127617/> |
| TLV | Palbociclib | LWCMEA | <https://www.tlv.se/beslut/beslut-lakemedel/begransad-subventiorkiv/2017-06-19-ibrance-ingar-i-hogkostnadsskyddet-med-begransning.html> |
| NICE | Palbociclib | LWCMEA | <https://www.nice.org.uk/guidance/ta495/chapter/1-Recommendations> |
| SMC | Nintedanib-2 | LWCMEA | <https://www.scottishmedicines.org.uk/medicines-advice/nintedanib-vargatef-fullsubmission-102715/> |
| NICE | Nintedanib-2 | LWCMEA | <https://www.nice.org.uk/guidance/ta347> |
| PBAC | Lenvatinib | LWCMEA | <http://www.pbs.gov.au/info/industry/listing/elements/pbac-meetings/psd/2016-07/lenvatinib-psd-july-2016> |
| SMC | Lenvatinib | LWCMEA | <https://www.scottishmedicines.org.uk/medicines-advice/lenvatinib-lenvima-fullsubmission-117916/> |
| NICE | Lenvatinib | LWCMEA | <https://www.nice.org.uk/guidance/ta535> |
| PBAC | Ceritinib | LWC | <http://www.pbs.gov.au/info/industry/listing/elements/pbac-meetings/psd/2016-11/ceritinib-psd-november-2016> |
| SMC | Ceritinib | LWCMEA | <https://www.scottishmedicines.org.uk/medicines-advice/ceritinib-zykadia-fullsubmission-109715/> |
| TLV | Ceritinib | LWCMEA | <https://www.tlv.se/beslut/beslut-lakemedel/generell-subventiorkiv/2015-12-14-zykadia-ingar-i-hogkostnadsskyddet.html> |
| NICE | Ceritinib | LWCMEA | <https://www.nice.org.uk/guidance/ta395/chapter/4-Committee-discussion> |
| PBAC | Trametinib | LWCMEA | <http://www.pbs.gov.au/info/industry/listing/elements/pbac-meetings/psd/2014-11/trametinib-psd-11-2014> |
| SMC | Trametinib | LWCMEA | <https://www.scottishmedicines.org.uk/medicines-advice/trametinib-mekinist-fullsubmission-116116/> |
| TLV | Trametinib | LWCMEA | <https://www.tlv.se/beslut/beslut-lakemedel/begransad-subventiorkiv/2016-06-22-mekinist-ingar-i-hogkostnadsskyddet-med-begransning.html> |
| NICE | Trametinib | LWCMEA | <https://www.nice.org.uk/guidance/ta396> |
| PBAC | Ponatinib | LWC | <http://www.pbs.gov.au/info/industry/listing/elements/pbac-meetings/psd/2015-07/ponatinib-psd-july-2015> |
| NICE | Ponatinib | LWCMEA | <https://www.nice.org.uk/guidance/ta451> |
| PBAC | Dabrafenib-1 | LWCMEA | <http://www.pbs.gov.au/info/industry/listing/elements/pbac-meetings/psd/2013-07/dabrafenib> |
| SMC | Dabrafenib-1 | LWCMEA | <https://www.scottishmedicines.org.uk/medicines-advice/dabrafenib-tafinlar-fullsubmission-102315/> |
| NICE | Dabrafenib-1 | LWCMEA | <https://www.nice.org.uk/guidance/ta321> |
| PBAC | Axitinib | LWCMEA | <http://www.pbs.gov.au/info/industry/listing/elements/pbac-meetings/psd/2014-11/axitinib-psd-11-2014> |
| SMC | Axitinib | LWCMEA | <https://www.scottishmedicines.org.uk/medicines-advice/axitinib-inlyta-resubmission-85513/> |
| NICE | Axitinib | LWCMEA | <https://www.nice.org.uk/guidance/ta333/chapter/1-Guidance> |
| PBAC | Crizotinib-1 | LWCMEA | <http://www.pbs.gov.au/info/industry/listing/elements/pbac-meetings/psd/2014-11/crizotinib-psd-11-2014> |
| SMC | Crizotinib-1 | LWCMEA | <https://www.scottishmedicines.org.uk/medicines-advice/crizotinib-xalkori-resubmission-86513/> |
| TLV | Crizotinib-1 | LWCMEA | <https://www.tlv.se/beslut/beslut-lakemedel/begransad-subventiorkiv/2014-03-05-xalkori-ingar-i-hogkostnadsskyddet-med-begransning.html> |
| NICE | Crizotinib-1 | LWCMEA | <https://www.nice.org.uk/guidance/ta422> |
| SMC | Crizotinib-2 | LWCMEA | <https://www.scottishmedicines.org.uk/medicines-advice/crizotinib-xalkori-fullsubmission-115216/> |
| NICE | Crizotinib-2 | LWCMEA | <https://www.nice.org.uk/guidance/ta406/chapter/4-Committee-discussion> |
| PBAC | Blinatumomab | LWCMEA | <http://www.pbs.gov.au/info/industry/listing/elements/pbac-meetings/psd/2016-07/blinatumomab-psd-july-2016> |
| SMC | Blinatumomab | LWCMEA | <https://www.scottishmedicines.org.uk/medicines-advice/blinatumomab-blincyto-fullsubmission-114516/> |
| NICE | Blinatumomab | LWCMEA | <https://www.nice.org.uk/guidance/ta450> |
| PBAC | Pembrolizumab-3 | LWCMEA | <http://www.pbs.gov.au/info/industry/listing/elements/pbac-meetings/psd/2018-07/Pembrolizumab-Keytruda-psd-july-2018> |
| SMC | Pembrolizumab-3 | LWCMEA | <https://www.scottishmedicines.org.uk/medicines-advice/pembrolizumab-keytruda-fullsubmission-123917/> |
| NICE | Pembrolizumab-3 | LWCMEA | <https://www.nice.org.uk/guidance/ta531> |
| PBAC | Pembrolizumab-1 | LWCMEA | <http://www.pbs.gov.au/info/industry/listing/elements/pbac-meetings/psd/2015-03/pembrolizumab-keytruda-psd-03-2015> |
| SMC | Pembrolizumab-1 | LWCMEA | <https://www.scottishmedicines.org.uk/medicines-advice/pembrolizumab-keytruda-fullsubmission-108615/> |
| NICE | Pembrolizumab-1 | LWCMEA | <https://www.nice.org.uk/guidance/ta366/chapter/3-The-companys-submission> |
| PBAC | Nivolumab-3 | LWCMEA | <http://www.pbs.gov.au/pbs/industry/listing/elements/pbac-meetings/psd/2017-03/nivolumab-rcc-psd-march-2017> |
| SMC | Nivolumab-3 | LWCMEA | <https://www.scottishmedicines.org.uk/medicines-advice/nivolumab-opdivo-resubmission-118816/> |
| NICE | Nivolumab-3 | LWCMEA | <https://www.nice.org.uk/guidance/ta417> |
| PBAC | Nivolumab-1 | LWCMEA | <http://www.pbs.gov.au/info/industry/listing/elements/pbac-meetings/psd/2015-11/nivolumab-opdivo-psd-11-2015> |
| SMC | Nivolumab-1 | LWCMEA | <https://www.scottishmedicines.org.uk/medicines-advice/nivolumab-opdivo-resubmission-112016/> |
| PBAC | Nivolumab-6 | LWCMEA | <http://www.pbs.gov.au/info/industry/listing/elements/pbac-meetings/psd/2018-07/Nivolumab-psd-july-2018> |
| SMC | Nivolumab-6 | LWCMEA | <https://www.scottishmedicines.org.uk/medicines-advice/nivolumab-opdivo-fullsubmission-118716/> |
| NICE | Nivolumab-6 | LWCMEA | <https://www.nice.org.uk/guidance/ta400> |
| PBAC | Obinutuzumab-1 | LWCMEA | <http://www.pbs.gov.au/pbs/industry/listing/elements/pbac-meetings/psd/2015-03/obinutuzumab-gazyva-psd-03-2015> |
| NICE | Obinutuzumab-1 | LWCMEA | <https://www.nice.org.uk/guidance/ta343/chapter/3-The-companys-submission> |
| PBAC | Trastuzumab emtansine-1 | LWC | <https://www.pbs.gov.au/industry/listing/elements/pbac-meetings/psd/2014-11/files/pertuzumab-trastuzumab-psd-11-2014.pdf> |
| SMC | Trastuzumab emtansine-1 | LWCMEA | <https://www.scottishmedicines.org.uk/medicines-advice/trastuzumab-emtansine-kadcyla-resubmission-99014/> |
| NICE | Trastuzumab emtansine-1 | LWCMEA | <https://www.nice.org.uk/guidance/ta458> |
| PBAC | Brentuximab Vedotin-2 | LWCMEA | <http://www.pbs.gov.au/info/industry/listing/elements/pbac-meetings/psd/2014-07/brentuximab-vedotin-psd-07-2014> |
| TLV | Brentuximab Vedotin-2 | LWCMEA | <https://www.tlv.se/beslut/beslut-lakemedel/begransad-subventiorkiv/2013-06-21-adcetris-ingar-i-hogkostnadsskyddet-med-begransning.html> |
| NICE | Brentuximab Vedotin-2 | LWCMEA | <https://www.nice.org.uk/guidance/ta478> |
| PBAC | Brentuximab Vedotin-3 | LWCMEA | <http://www.pbs.gov.au/info/industry/listing/elements/pbac-meetings/psd/2016-11/brentuximab-post-asct-naive-psd-november-2016> |
| TLV | Brentuximab Vedotin-3 | LWCMEA | <https://www.tlv.se/beslut/beslut-lakemedel/begransad-subventiorkiv/2013-06-21-adcetris-ingar-i-hogkostnadsskyddet-med-begransning.html> |
| NICE | Brentuximab Vedotin-3 | LWCMEA | <https://www.nice.org.uk/guidance/ta524/chapter/1-Recommendations> |
| PBAC | Ofatumumab | LWCMEA | <http://www.pbs.gov.au/info/industry/listing/elements/pbac-meetings/psd/2014-11/ofatumumab-psd-11-2014> |
| SMC | Ofatumumab | LWCMEA | <https://www.scottishmedicines.org.uk/medicines-advice/ofatumumab-arzerra-fullsubmission-103715/> |
| TLV | Ofatumumab | LWC | <https://www.tlv.se/beslut/beslut-lakemedel/begransad-subvention/arkiv/2015-01-30-arzerra-ingar-i-hogkostnadsskyddet-med-begransning.html> |
| NICE | Ofatumumab | LWCMEA | <https://www.nice.org.uk/guidance/ta344> |
| NICE | Carfilzomib | LWCMEA | <https://www.nice.org.uk/guidance/ta457> |
| SMC | carfilzomib | LWCMEA | <https://www.scottishmedicines.org.uk/medicines-advice/carfilzomib-kyprolis-fullsubmission-124217/> |
| SMC | Pazopanib-1 | LWCMEA | <https://www.scottishmedicines.org.uk/media/2121/pazopanib_votrient_final_february_2011doc_for_website.pdf> |
| NICE | Pazopanib-1 | LWCMEA | <https://www.nice.org.uk/guidance/ta215/resources/pazopanib-for-the-firstline-treatment-of-advanced-renal-cell-carcinoma-pdf-82600251340741> |
| PBAC | Pazopanib-1 | LWC | <http://www.pbs.gov.au/info/industry/listing/elements/pbac-meetings/psd/2012-03/pazopanib> |
| TLV | Pazopanib-1 | LWCMEA | <https://www.tlv.se/download/18.467926b615d084471ac32495/1510316371588/bes-101210-votrient.pdf> |
| SMC | Trifluridine–tipiracil | LWCMEA | <https://www.scottishmedicines.org.uk/media/2441/trifluridine_tipiracil_lonsurf_final_jan_2017_for_website.pdf> |
| NICE | Trifluridine–tipiracil | LWCMEA | <https://www.nice.org.uk/guidance/ta405/chapter/2-The-technology> |
| PBAC | Vismodegib | LWCMEA | <http://www.pbs.gov.au/industry/listing/elements/pbac-meetings/psd/2016-03/files/vismodegib-psd-march-2016.pdf> |
| NICE | Paclitaxel | LWCMEA | <https://www.nice.org.uk/guidance/ta476/resources/paclitaxel-as-albuminbound-nanoparticles-with-gemcitabine-for-untreated-metastatic-pancreatic-cancer-pdf-82604969382085> |
| PBAC | Paclitaxel | LWC | <http://www.pbs.gov.au/pbs/industry/listing/elements/pbac-meetings/psd/2014-03/paclitaxel-nanoparticle-albumin-bound-psd-03-2014> |
| SMC | Cabazitaxel | LWCMEA | <https://www.scottishmedicines.org.uk/medicines-advice/cabazitaxel-jevtana-resubmission-73511/> |
| NICE | Cabazitaxel | LWCMEA | <https://www.nice.org.uk/guidance/ta391> |
| SMC | Rituximab-1 | LWCMEA | <https://www.scottishmedicines.org.uk/media/2253/rituximab_subcutaneous_inj_mabthera_final_june_2014_for_website.pdf> |
| NICE | Rituximab-1 | LWC | <https://www.nice.org.uk/guidance/ta243> |
| PBAC | Rituximab-1 | LWCMEA | <http://www.pbs.gov.au/industry/listing/elements/pbac-meetings/psd/2014-11/files/rituximab-psd-11-2014.pdf> |
| SMC | Ipilimumab-1 | LWCMEA | <https://www.scottishmedicines.org.uk/media/1869/ipilimumab_yervoy_resubmission_final_march_2013_for_website.pdf> |
| NICE | Ipilimumab-1 | LWCMEA | <https://www.nice.org.uk/guidance/ta268/resources/ipilimumab-for-previously-treated-advanced-unresectable-or-metastatic-melanoma-pdf-82600558710469> |
| PBAC | Ipilimumab-1 | LWCMEA | <https://www.pbs.gov.au/industry/listing/elements/pbac-meetings/psd/2012-11/ipilimumab.pdf> |
| SMC | Brentuximab Vedotin-1 | LWC | <https://www.scottishmedicines.org.uk/media/1363/dad_brentuximab_vedotin__adcetris__final_sept_2014_amended_numbering_for_website.pdf> |
| NICE | Brentuximab Vedotin-1 | LWCMEA | <https://www.nice.org.uk/guidance/ta524/resources/brentuximab-vedotin-for-treating-cd30positive-hodgkin-lymphoma-pdf-82606840474309> |
| PBAC | Brentuximab Vedotin-1 | LWCMEA | <https://www.pbs.gov.au/industry/listing/elements/pbac-meetings/psd/2016-11/files/brentuximab-post-asct-psd-november-2016.pdf> |
| TLV | Brentuximab Vedotin-1 | LWC | <https://www.tlv.se/download/18.467926b615d084471ac33505/1510316391626/bes130620-adcetris.pdf> |
| SMC | Pertuzumab-2 | LWCMEA | <https://www.scottishmedicines.org.uk/medicines-advice/pertuzumab-perjeta-resubmission-112116/> |
| NICE | Pertuzumab-2 | LWCMEA | <https://www.nice.org.uk/guidance/ta424> |
| PBAC | Pertuzumab-2 | LWCMEA | <https://www.pbs.gov.au/industry/listing/elements/pbac-meetings/psd/2014-11/files/pertuzumab-trastuzumab-psd-11-2014.pdf> |
| PBAC | Cobimetinib | LWCMEA | <http://www.pbs.gov.au/industry/listing/elements/pbac-meetings/psd/2016-03/files/cobimetinib-vemurafenib-psd-march-2016.pdf> |
| SMC | Ribociclib | LWCMEA | <https://www.scottishmedicines.org.uk/medicines-advice/ribociclib-kisqali-fullsubmission-129518/> |
| NICE | Ribociclib | LWCMEA | <https://www.nice.org.uk/guidance/ta496/resources/ribociclib-with-an-aromatase-inhibitor-for-previously-untreated-hormone-receptorpositive-her2negative-locally-advanced-or-metastatic-breast-cancer-pdf-82605090314437> |
| TLV | Ribociclib | LWCMEA | <https://www.tlv.se/download/18.5843e621161763dd35abaf67/1518427542090/bes180125_%20kisqali.pdf> |
| SMC | Obinutuzumab-2 | LWCMEA | <https://www.scottishmedicines.org.uk/media/2057/obinutuzumab_gazyvaro_final_feb_2017_updated_130217_for_website.pdf> |
| NICE | Obinutuzumab-2 | LWCMEA | <https://www.nice.org.uk/guidance/ta472> |
| SMC | Nivolumab-2 | LWCMEA | <https://www.scottishmedicines.org.uk/media/2052/nivolumab_opdivo_final_sept_2016_final_amended_150916_for_website.pdf> |
| NICE | Nivolumab-2 | LWCMEA | <https://www.nice.org.uk/guidance/ta484> |
| PBAC | Nivolumab-2 | LWCMEA | <http://www.pbs.gov.au/industry/listing/elements/pbac-meetings/psd/2017-03/files/nivolumab-psd-march-2017.pdf> |
| SMC | Nivolumab-4 | LWCMEA | <https://www.scottishmedicines.org.uk/media/2050/nivolumab_opdivo_final_august_2017_for_website.pdf> |
| NICE | Nivolumab-4 | LWCMEA | <https://www.nice.org.uk/guidance/ta490> |
| PBAC | Nivolumab-4 | LWCMEA | <http://www.pbs.gov.au/industry/listing/elements/pbac-meetings/psd/2017-11/files/nivolumab-scchn-psd-november-2017.pdf> |
| PBAC | Ramucirumab-1 | LWCMEA | <http://www.pbs.gov.au/industry/listing/elements/pbac-meetings/psd/2018-03/files/ramucirumab-psd-march-2018.pdf> |
| SMC | Everolimus-3 | LWCMEA | <https://www.scottishmedicines.org.uk/media/1696/everolimus_afinitor_2nd_resub_final_march_2016_for_website.pdf> |
| NICE | Everolimus-3 | LWCMEA | <https://www.nice.org.uk/guidance/ta421> |
| PBAC | Everolimus-3 | LWC | <http://www.pbs.gov.au/industry/listing/elements/pbac-meetings/psd/2013-07/everolimus-psd-07-2013.pdf> |
| PBAC | Everolimus-4 | LWCMEA | <http://www.pbs.gov.au/pbs/industry/listing/elements/pbac-meetings/psd/2013-04/everolimus> |
| TLV | Everolimus-4 | LWCMEA | <https://www.tlv.se/download/18.467926b615d084471ac2fff1/1510316383255/bes120427-votubia.pdf> |
| SMC | Bosutinib | LWCMEA | <https://www.scottishmedicines.org.uk/media/1353/bosutinib__bosulif__resubmission_final_jan_2015_for_website.pdf> |
| NICE | Bosutinib | LWCMEA | <https://www.nice.org.uk/guidance/ta401> |
| TLV | Bosutinib | LWC | <https://www.tlv.se/beslut/beslut-lakemedel/generell-subvention/arkiv/2013-10-08-bosulif-ingar-i-hogkostnadsskyddet.html> |
| SMC | Vemurafenib | LWCMEA | <https://www.scottishmedicines.org.uk/media/2474/vemurafenib__zelboraf__resubmission_final_nov_2013_for_website.pdf> |
| NICE | Vemurafenib | LWCMEA | <https://www.nice.org.uk/guidance/ta269> |
| PBAC | Vemurafenib | LWCMEA | [https://www.pbs.gov.au/industry/listing/elements/pbac-meetings/psd/2013-03/vemurafenib-psd-03-2013.pdfhttp://www.pbs.gov.au/industry/listing/elements/pbac-meetings/pbac-outcomes/2017-04/positive%20recommendations-04-2017.pdf](https://www.pbs.gov.au/industry/listing/elements/pbac-meetings/psd/2013-03/vemurafenib-psd-03-2013.pdf) |
| TLV | Vemurafenib | LWCMEA | <https://www.tlv.se/download/18.467926b615d084471ac329fc/1510316394590/bes150331-zeloboraf.pdf> |
| SMC | Ruxolitinib-1 | LWCMEA | <https://www.scottishmedicines.org.uk/medicines-advice/ruxolitinib-jakavi-fullsubmission-86713/> |
| NICE | Ruxolitinib-1 | LWCMEA | <https://www.nice.org.uk/guidance/ta386> |
| PBAC | Ruxolitinib-1 | LWCMEA | <http://www.pbs.gov.au/industry/listing/elements/pbac-meetings/psd/2015-03/Files/ruxolitinib-psd-march-2015.pdf> |
| TLV | Ruxolitinib-1 | LWC | <https://www.tlv.se/beslut/beslut-lakemedel/begransad-subvention/arkiv/2014-04-10-jakavi-ingar-i-hogkostnadsskyddet-med-begransning.html> |
| SMC | Regorafenib-1 | LWCMEA | <https://www.scottishmedicines.org.uk/medicines-advice/regorafenib-stivarga-fullsubmission-103115/> |
| NICE | Regorafenib-1 | LWCMEA | <https://www.nice.org.uk/guidance/ta488> |
| TLV | Regorafenib-1 | LWC | <https://www.tlv.se/download/18.467926b615d084471ac335b1/1510316392284/bes160204_stivarga.pdf> |
| SMC | Cabozantinib-1 | LWCMEA | <https://www.scottishmedicines.org.uk/medicines-advice/cabozantinib-cabometyx-fullsubmission-123417/> |
| NICE | Cabozantinib-1 | LWCMEA | <https://www.nice.org.uk/guidance/ta463> |
| PBAC | Cabozantinib-1 | LWC | <http://www.pbs.gov.au/industry/listing/elements/pbac-meetings/psd/2017-12/files/cabozantinib-psd-12-2017.pdf> |
| TLV | Cabozantinib-1 | LWCMEA | <https://www.tlv.se/download/18.513bc0a61625c3aed9e5ae49/1522246130614/bes180322_cabometyx.pdf> |
| SMC | Ibrutinib-1 | LWCMEA | <https://www.scottishmedicines.org.uk/medicines-advice/ibrutinib-imbruvica-cll-fullsubmission-115116/> |
| NICE | Ibrutinib-1 | LWCMEA | <https://www.nice.org.uk/guidance/ta429/resources/ibrutinib-for-previously-treated-chronic-lymphocytic-leukaemia-and-untreated-chronic-lymphocytic-leukaemia-with-17p-deletion-or-tp53-mutation-pdf-82604672090053> |
| PBAC | Ibrutinib-1 | LWC | <https://www.pbs.gov.au/industry/listing/elements/pbac-meetings/psd/2016-11/files/ibrutinib-cll-sll-psd-november-2016.pdf> |
| SMC | Ibrutinib-2 | LWCMEA | <https://www.scottishmedicines.org.uk/medicines-advice/ibrutinib-imbruvica-mcl-fullsubmission-115016/> |
| NICE | Ibrutinib-2 | LWCMEA | <https://www.nice.org.uk/guidance/ta502> |
| NICE | Ibrutinib-3 | LWCMEA | <https://www.nice.org.uk/guidance/ta491> |
| SMC | Aflibercept-5 | LWCMEA | <https://www.scottishmedicines.org.uk/media/1218/aflibercept_zaltrap_resubmission_final_february_2014_for_website.pdf> |
| SMC | Idelalisib-2 | LWCMEA | <https://www.scottishmedicines.org.uk/media/1813/idelalisib_zydelig_final_april_2015_for_website.pdf> |
| PBAC | Idelalisib-2 | LWC | <https://www.pbs.gov.au/industry/listing/elements/pbac-meetings/psd/2016-07/files/idelalisib-fl-psd-july-2016.pdf> |
| NICE | Talimogene laherparepvec | LWCMEA | <https://www.nice.org.uk/guidance/ta410/resources/talimogene-laherparepvec-for-treating-unresectable-metastatic-melanoma-pdf-82604596507333> |
| TLV | Venetoclax | LWCMEA | <https://www.tlv.se/download/18.577a4290162f616250872b1a/1525249405685/bes180420_venclyxto.pdf> |
| SMC | Enzalutamide-1 | LWCMEA | <https://www.scottishmedicines.org.uk/media/1629/enzalutamide_xtandi_final_october_2013_amended_081113.pdf> |
| NICE | Enzalutamide-1 | LWCMEA | <https://www.nice.org.uk/guidance/ta316/resources/enzalutamide-for-metastatic-hormonerelapsed-prostate-cancer-previously-treated-with-a-docetaxelcontaining-regimen-pdf-82602429802693> |
| PBAC | Enzalutamide-1 | LWCMEA | <http://www.pbs.gov.au/industry/listing/elements/pbac-meetings/psd/2014-07/enzalutamide-psd-07-2014.pdf> |
| TLV | Enzalutamide-1 | LWCMEA | <https://www.tlv.se/download/18.467926b615d084471ac3037d/1510316357231/Bes150612-xtandi.pdf> |
| SMC | Enzalutamide-2 | LWCMEA | <https://www.scottishmedicines.org.uk/medicines-advice/enzalutamide-xtandi-irp-106615/> |
| NICE | Enzalutamide-2 | LWCMEA | <https://www.nice.org.uk/guidance/ta377> |
| PBAC | Enzalutamide-2 | LWCMEA | <https://www.pbs.gov.au/industry/listing/elements/pbac-meetings/psd/2014-07/enzalutamide-psd-07-2014.pdf> |
| TLV | Enzalutamide-2 | LWCMEA | <https://www.tlv.se/beslut/beslut-lakemedel/generell-subvention/arkiv/2015-06-15-xtandi-ingar-i-hogkostnadsskyddet.html> |
| SMC | Abiraterone Acetate-2 | LWCMEA | <https://www.scottishmedicines.org.uk/medicines-advice/abiraterone-zytiga-irp-87313/> |
| NICE | Abiraterone Acetate-2 | LWCMEA | <https://www.nice.org.uk/guidance/ta387> |
| SMC | Abiraterone Acetate-1 | LWCMEA | <https://www.scottishmedicines.org.uk/medicines-advice/abiraterone-zytiga-resubmission-76412/> |
| NICE | Abiraterone Acetate-1 | LWCMEA | <https://www.nice.org.uk/guidance/ta259> |
| PBAC | Abiraterone Acetate-1 | LWCMEA | <http://www.pbs.gov.au/info/industry/listing/elements/pbac-meetings/psd/2012-11/abiraterone> |
| SMC | Pomalidomide | LWCMEA | <https://www.scottishmedicines.org.uk/medicines-advice/pomalidomide-imnovid-resubmission-97214/> |
| NICE | Pomalidomide | LWCMEA | <https://www.nice.org.uk/guidance/ta427> |
| PBAC | Pomalidomide | LWCMEA | <http://www.pbs.gov.au/industry/listing/elements/pbac-meetings/psd/2014-07/pomalidomide-psd-07-2014.pdf> |